Philadelphia chromosome-positive chronic myeloid leukemia

Clinical trials for Philadelphia chromosome-positive chronic myeloid leukemia explained in plain language.

Never miss a new study

Get alerted when new Philadelphia chromosome-positive chronic myeloid leukemia trials appear

Sign up with your email to follow new studies for Philadelphia chromosome-positive chronic myeloid leukemia, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New CML drug shows better tolerability in Head-to-Head trial

Disease control Ongoing

This study tests whether asciminib is easier to tolerate than nilotinib in adults newly diagnosed with a type of leukemia called Philadelphia chromosome-positive CML. About 568 participants take either asciminib once daily or nilotinib twice daily. The main goal is to see how lon…

Matched conditions: PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA

Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control

Last updated Aug 28, 2026 00:00 UTC

Philadelphia chromosome-positive chronic myeloid leukemia

Get alerted when new Philadelphia chromosome-positive chronic myeloid leukemia trials appear

New CML drug shows better tolerability in Head-to-Head trial